151 related articles for article (PubMed ID: 36420802)
1.
Komrokji R; Al Ali N; Chan O; Sweet K; Kuykendall A; Lancet J; Padron E; Sallman DA
Haematologica; 2023 Apr; 108(4):1168-1172. PubMed ID: 36420802
[No Abstract] [Full Text] [Related]
2. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536
[TBL] [Abstract][Full Text] [Related]
4. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.
Caramazza D; Lasho TL; Finke CM; Gangat N; Dingli D; Knudson RA; Siragusa S; Hanson CA; Pardanani A; Ketterling RP; Tefferi A
Leukemia; 2010 Dec; 24(12):2120-2. PubMed ID: 20861910
[No Abstract] [Full Text] [Related]
5. Histiocytoid Sweet syndrome harboring an isocitrate dehydrogenase 1 mutation: A case report and retrospective analysis of 29 cases of histiocytoid Sweet syndrome.
Libby TJ; Fleming K; Amin B
J Cutan Pathol; 2019 Apr; 46(4):290-292. PubMed ID: 30632174
[TBL] [Abstract][Full Text] [Related]
6. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
[TBL] [Abstract][Full Text] [Related]
7. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Andrulis M; Capper D; Luft T; Hartmann C; Zentgraf H; von Deimling A
Leuk Res; 2010 Aug; 34(8):1091-3. PubMed ID: 20227112
[TBL] [Abstract][Full Text] [Related]
8. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
9. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q).
Pardanani A; Patnaik MM; Lasho TL; Mai M; Knudson RA; Finke C; Ketterling RP; McClure RF; Tefferi A
Leukemia; 2010 Jul; 24(7):1370-2. PubMed ID: 20485375
[No Abstract] [Full Text] [Related]
10. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
11. [IDH1/2 gene mutations in myelodysplastic syndromes].
Yoshida K; Sanada M; Ogawa S
Rinsho Ketsueki; 2012 Apr; 53(4):391-5. PubMed ID: 22687971
[No Abstract] [Full Text] [Related]
12. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
13. Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and
Alkhaldi H; Sewell D; Ning Y; Kallen ME; Emadi A; Hardy NM; Baer MR
Leuk Lymphoma; 2022 Dec; 63(12):3000-3003. PubMed ID: 35938721
[TBL] [Abstract][Full Text] [Related]
14. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Harding JJ; Lowery MA; Shih AH; Schvartzman JM; Hou S; Famulare C; Patel M; Roshal M; Do RK; Zehir A; You D; Selcuklu SD; Viale A; Tallman MS; Hyman DM; Reznik E; Finley LWS; Papaemmanuil E; Tosolini A; Frattini MG; MacBeth KJ; Liu G; Fan B; Choe S; Wu B; Janjigian YY; Mellinghoff IK; Diaz LA; Levine RL; Abou-Alfa GK; Stein EM; Intlekofer AM
Cancer Discov; 2018 Dec; 8(12):1540-1547. PubMed ID: 30355724
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
16. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
[TBL] [Abstract][Full Text] [Related]
17. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
[TBL] [Abstract][Full Text] [Related]
18. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Holtan SG; Pardanani A; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Leukemia; 2010 Jul; 24(7):1283-9. PubMed ID: 20485371
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T
Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
[TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]